Skip to main content

Table 3 HPV 16/18/31/33/45/52/58 type-specific relative contribution in precancerous cervical lesions HPV-positive, by region

From: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease

Region

HPV type

Low grade

High grade

HPV-positive

RC

95%CI

HPV-positive

RC

95%CI

Africa

HPV-16

517

16.8

(13.7-20.3)

251

30.3

(24.7-36.4)

HPV-18

517

8.3

(6.1-11.0)

251

9.2

(5.9-13.4)

HPV-31

432

6.5

(4.4-9.2)

245

8.2

(5.0-12.3)

HPV-33

517

8.5

(6.3-11.3)

235

8.9

(5.6-13.3)

HPV-45

432

4.4

(2.7-6.8)

245

4.1

(2.0-7.4)

HPV-52

432

11.8

(8.9-15.2)

245

11.0

(7.4-15.6)

HPV-58

517

10.8

(8.3-13.8)

251

11.2

(7.5-15.7)

Eastern Asia

HPV-16

2,790

21.1

(19.6-22.6)

3,693

37.9

(36.4-39.5)

HPV-18

2,790

8.3

(7.3-9.4)

3,693

7.4

(6.5-8.3)

HPV-31

2,552

4.4

(3.7-5.3)

3,596

6.9

(6.1-7.8)

HPV-33

2,790

5.0

(4.2-5.8)

3,693

9.9

(9.0-11.0)

HPV-45

2,549

1.2

(0.8-1.7)

3,148

2.0

(1.6-2.6)

HPV-52

2,624

18.2

(16.8-19.8)

3,469

21.3

(20.0-22.7)

HPV-58

2,781

13.5

(12.3-14.9)

3,647

19.6

(18.3-20.9)

Western/Central Asia

HPV-16

237

30.8

(25.0-37.1)

79

68.4

(56.9-78.4)

HPV-18

237

6.8

(3.9-10.7)

79

6.3

(2.1-14.2)

HPV-31

229

4.4

(2.1-7.9)

63

23.8

(14.0-36.2)

HPV-33

210

7.1

(4.1-11.8)

31

9.7

(2.0-25.8)

HPV-45

189

2.1

(0.6-5.8)

28

7.1

(0.9-23.5)

HPV-52

72

2.8

(0.3-9.7)

20

0.0

(0.0-16.8)

HPV-58

189

6.4

(3.3-10.8)

28

10.7

(2.3-28.2)

South/Central America

HPV-16

2,692

25.1

(23.5-26.8)

1,896

52.9

(50.6-55.1)

HPV-18

2,690

6.8

(5.9-7.9)

1,886

9.4

(8.2-10.9)

HPV-31

2,504

5.2

(4.4-6.1)

1,837

10.6

(9.2-12.1)

HPV-33

2,517

7.5

(6.5-8.6)

1,776

6.5

(5.3-7.7)

HPV-45

2,166

4.5

(3.7-5.5)

1,669

4.8

(3.8-5.9)

HPV-52

2,127

5.1

(4.2-6.1)

1,587

6.3

(5.2-7.6)

HPV-58

2,220

6.9

(5.8-8.0)

1,589

9.5

(8.1-11.1)

North America

HPV-16

5,532

24.7

(23.6-25.6)

4,598

56.7

(55.3-58.2)

HPV-18

5,532

9.5

(8.7-10.3)

4,598

9.6

(8.8-10.5)

HPV-31

5,532

8.9

(8.1-9.6)

4,598

13.1

(12.1-14.1)

HPV-33

5,317

4.2

(3.7-4.8)

4,598

7.6

(6.9-8.4)

HPV-45

5,415

5.6

(5.0-6.2)

4,397

4.8

(4.2-5.5)

HPV-52

4,839

10.7

(9.9-11.6)

4,205

10.3

(9.4-11.3)

HPV-58

5,213

7.6

(6.9-8.3)

4,397

6.8

(6.1-7.6)

Europe

HPV-16

14,319

25.9

(25.2-26.6)

8,348

54.4

(53.3-55.5)

HPV-18

14,256

9.1

(8.6-9.6)

8,214

7.7

(7.2-8.3)

HPV-31

13,166

12.5

(12.0-13.1)

7,930

12.4

(11.6-13.1)

HPV-33

13,186

6.6

(6.2-7.1)

7,844

9.4

(8.7-10.0)

HPV-45

10,472

4.6

(4.2-5.1)

6,244

3.8

(3.3-4.3)

HPV-52

9,577

8.3

(7.8-8.9)

6,067

7.2

(6.6-7.9)

HPV-58

10,489

6.7

(6.2-7.2)

6,278

5.8

(5.2-6.4)

Oceania

HPV-16

385

24.7

(20.5-29.3)

924

53.9

(50.6-57.2)

HPV-18

385

8.6

(6.0-11.8)

924

9.6

(7.8-11.7)

HPV-31

385

13.3

(10.0-17.0)

924

12.3

(10.3-14.6)

HPV-33

385

5.7

(3.6-8.5)

924

7.9

(6.2-9.8)

HPV-45

385

6.5

(4.3-9.4)

924

4.2

(3.0-5.7)

HPV-52

385

11.4

(8.4-15.0)

924

12.2

(10.2-14.5)

HPV-58

385

9.1

(6.4-12.4)

924

5.8

(4.4-7.6)

  1. Low-grade, includes ASCUS, LSIL and CIN1; High-grade, includes HSIL, CIN2 and CIN3.
  2. “RC”: Relative Contribution; “95%CI”: 95% Confidence Interval.
  3. Additional information: HPV type specific relative contribution: Numerator = includes either single or multiple infections, thus the total sum of % can exceed 100%; Denominator = ”Tested” cases that stands for the HPV/DNA positive cases from studies testing for the HPV type in question, thus denominators vary by type.
  4. The data source does not give specific information for HPV 6 and 11.
  5. 17. Data from Guan et al., IJC, 2012.